Fuda Cancer Hospital
Uterine cancer treatment cost in China typically runs from $9,800 to $18,500 for minimally invasive surgical interventions. Key procedures like Hysterectomy with DaVinci robot costs $19,500 to $27,000. Total expenses depend on the cancer stage, hospital tier, and specific therapeutic mix. Patients often see 40-60% savings compared to the US. Top cities for care include Guangzhou, Shanghai, and Beijing.
Typical Uterine Cancer Treatment Costs in China
Bookimed Expert Insight: For advanced or late-stage cases, specialized centers offer high value through non-traditional interventions. Fuda Cancer Hospital utilizes Joint Commission International (JCI) accredited standards for therapies like cryosurgery and NanoKnife. Patients seeking precision care benefit from experts like Dr. Liu Shi Xin at Xiamen Humanity Hospital. He specializes in advanced SBRT and VMAT radiotherapy techniques for abdominal malignancies.
| China | Turkey | Austria | |
| Radiotherapy for uterine cancer | from $12,000 | from $4,000 | from $6,922 |
| Laparoscopic Hysterectomy | from $9,800 | from $10,000 | from $15,000 |
| Hysterectomy (uterus removal) | from $11,500 | from $4,950 | from $15,000 |
| Hormone therapy | from $3,500 | from $404 | from $7,000 |
| Hysterectomy with DaVinci robot | from $19,500 | from $7,500 | from $16,000 |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
The standard first-line treatment for uterine cancer in China is surgical resection. Surgeons typically perform a total hysterectomy with bilateral salpingo-oophorectomy. This procedure removes the uterus, ovaries, and fallopian tubes. Specialized centers also use DaVinci robotic or laparoscopic techniques for minimally invasive staging.
Bookimed Expert Insight: Clinical data shows that Chinese oncology centers like Fuda Cancer Hospital often treat advanced cases where standard surgery is insufficient. These specialized facilities utilize cryosurgery and microwave hyperthermia to enhance results for late-stage patients. This focus on thermal ablation offers an alternative when traditional first-line systemic therapy needs local reinforcement.
Patient Consensus: Patients emphasize the importance of having a gynecologic oncologist perform the initial surgery. They note that pathology results from the first operation often dictate the entire future treatment plan.
Chinese oncologists treat endometrial cancer using domestic protocols developed by the Chinese Society of Clinical Oncology. These frameworks integrate international FIGO staging and NCCN standards. Specialists also follow specific molecular consensus to guide precision adjuvant therapies and immunotherapy for recurrent cases.
Bookimed Expert Insight: Leading Chinese experts often hold dual leadership roles in national bodies. Dr. Liu Shi Xin at Xiamen Humanity Hospital serves as Vice Chairman for both the Chinese Medical Association and the Chinese Anti-Cancer Association. This ensures treatment plans align strictly with high-level national research and the latest radiation oncology protocols.
Patient Consensus: Patients mention that treatment plans often change after the final pathology report. They recommend asking doctors how local recommendations compare specifically to international NCCN or FIGO benchmarks.
Immunotherapy is available for uterine cancer in China through immune checkpoint inhibitors like PD-1 inhibitors. National medical guidelines integrate these drugs for advanced or recurrent cases. Eligibility depends on molecular biomarker status. This requires specific pathology tests like MSI-H or dMMR profiles to predict drug response.
Bookimed Expert Insight: Chinese oncology centers demonstrate a distinct capability in managing late-stage uterine cancer. Fuda Cancer Hospital in Guangzhou has treated over 30,000 international patients using multimodal approaches. They often combine systemic immunotherapy with local therapies like cryosurgery or microwave hyperthermia. This strategy targets the primary tumor while immunotherapy manages microscopic spread throughout the body.
Patient Consensus: Patients emphasize molecular testing is a vital first step before therapy starts. They often recommend visiting large specialized cancer centers to ensure access to the latest drug combinations.
Minimally invasive uterine cancer treatments in China include cryosurgery, NanoKnife ablation, and robotic-assisted surgery. These options benefit high-risk patients who cannot tolerate traditional open surgery due to age or heart conditions. Specialized centers utilize precision radiotherapy like SBRT and brachytherapy to target tumors while sparing healthy tissue.
Bookimed Expert Insight: Fuda Cancer Hospital in Guangzhou provides over 10 types of minimally invasive therapies. This volume-based expertise is significant. While many clinics focus on standard chemotherapy, specialized Chinese centers often prioritize local ablation like microwave hyperthermia. This allows for effective treatment even in advanced stages where surgery is contraindicated.
Patient Consensus: Patients emphasize that non-surgical options like hormone therapy effectively preserve function but require rigorous monitoring. Many recommend seeking expert opinions on robotic approaches when traditional surgery is deemed too risky.
Young women in China can preserve fertility while treating endometrial cancer if they meet strict criteria. Eligibility requires stage IA, grade 1 tumors confined to the lining. Chinese medical centers utilize high-dose progestin therapy or hormone-releasing intrauterine devices. This approach avoids immediate hysterectomy for compliant patients.
Bookimed Expert Insight: Patient data from JCI-accredited centers like Fuda Cancer Hospital shows a strong shift toward minimally invasive therapies. Chinese oncology protocols often combine metabolic drugs like metformin with hormones to boost treatment response. This reflects a trend where major urban centers manage over 30,000 international cases annually. Such high volumes lead to more refined, fertility-sparing protocols compared to general surgery centers.
Patient Consensus: Patients emphasize that surveillance is intense and requires frequent biopsies and ultrasounds to monitor progress. Many note that a hysterectomy is often still required once childbearing is successfully completed.
Traditional Chinese medicine (TCM) in China is a supportive therapy for endometrial cancer alongside surgery and chemotherapy. Modalities like acupuncture and herbal formulations help manage treatment side effects. These methods aim to improve quality of life and immune function during conventional oncology care.
Bookimed Expert Insight: While clinics like Fuda Cancer Hospital focus on minimally invasive technologies like cryosurgery and NanoKnife, they operate within an integrative environment. Data shows that JCI-accredited facilities in China often use TCM to help patients tolerate these advanced procedures. This synergy aims to maintain the patient's physical strength so they do not have to delay scheduled conventional treatments.
Patient Consensus: Patients note that TCM is most valuable for day-to-day functioning and managing the heavy toll of chemotherapy. Most emphasize that herbal treatments should only supplement surgery rather than replacing it to avoid safety risks.